Arcturus Therapeutics Holdings Inc.
ARCT
Price:
$6.83
Market Cap:
$185.27M
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therap...[Read more]
Industry
Biotechnology
IPO Date
2013-05-22
Stock Exchange
NASDAQ
Ticker
ARCT
PE Ratio
[-2.78]
ROE
[-21.51%]
Current Ratio
[7.86]
Dividend Yield
[0%]
Enterprise Value
[26.78M]
Dividend History
The ROE as of December 2025 (TTM) for Arcturus Therapeutics Holdings Inc. (ARCT) is -21.51%
According to Arcturus Therapeutics Holdings Inc.’s latest financial reports and current stock price. The company's current ROE is -21.51%. This represents a change of 309.58% compared to the average of -5.25% of the last 4 quarters.
Arcturus Therapeutics Holdings Inc. (ARCT) Historical ROE (quarterly & annually)
How has ARCT ROE performed in the past?
The mean historical ROE of Arcturus Therapeutics Holdings Inc. over the last ten years is -52.11%. The current -21.51% ROE has changed -58.73% with respect to the historical average. Over the past ten years (40 quarters), ARCT's ROE was at its highest in in the December 2022 quarter at 43.41%. The ROE was at its lowest in in the March 2019 quarter at -108.34%.
Average
-52.11%
Median
-32.92%
Minimum
-159.69%
Maximum
3.46%
Arcturus Therapeutics Holdings Inc. (ARCT) ROE by Quarter and Year
Discovering the peaks and valleys of Arcturus Therapeutics Holdings Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 395.01%
Maximum Annual ROE = 3.46%
Minimum Annual Increase = -408.59%
Minimum Annual ROE = -159.69%
| Year | ROE | Change |
|---|---|---|
| 2024 | -33.59% | 214.71% |
| 2023 | -10.67% | -408.59% |
| 2022 | 3.46% | -103.88% |
| 2021 | -89.25% | 390.54% |
| 2020 | -18.19% | -81.95% |
| 2019 | -100.77% | -36.90% |
| 2018 | -159.69% | 395.01% |
| 2017 | -32.26% | -38.07% |
| 2016 | -52.09% | 85.70% |
| 2015 | -28.05% | -82.96% |
Arcturus Therapeutics Holdings Inc. (ARCT) Average ROE
How has ARCT ROE performed in the past?
The current ROE of Arcturus Therapeutics Holdings Inc. (ARCT) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-13.60%
5-year avg
-29.65%
10-year avg
-52.11%
Arcturus Therapeutics Holdings Inc. (ARCT) ROE vs. Peers
How is ARCT’s ROE compared to its peers?
Arcturus Therapeutics Holdings Inc.’s ROE is greater than Sagimet Biosciences Inc. (-42.39%), less than Humacyte, Inc. (449.27%), greater than Voyager Therapeutics, Inc. (-48.94%), greater than Entrada Therapeutics, Inc. (-26.42%), greater than Vanda Pharmaceuticals Inc. (-16.82%), greater than Achieve Life Sciences, Inc. (-196.68%), less than Foghorn Therapeutics Inc. (142.17%), greater than Immuneering Corporation (-146.28%), greater than Zura Bio Limited (-51.70%), greater than Atea Pharmaceuticals, Inc. (-32.55%),
| Company | ROE | Market cap |
|---|---|---|
| -42.39% | $196.86M | |
| 449.27% | $185.66M | |
| -48.94% | $241.84M | |
| -26.42% | $388.31M | |
| -16.82% | $307.28M | |
| -196.68% | $254.41M | |
| 142.17% | $258.99M | |
| -146.28% | $242.86M | |
| -51.70% | $252.94M | |
| -32.55% | $241.42M |
Build a custom stock screener for Arcturus Therapeutics Holdings Inc. (ARCT) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Arcturus Therapeutics Holdings Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Arcturus Therapeutics Holdings Inc. (ARCT) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Arcturus Therapeutics Holdings Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Arcturus Therapeutics Holdings Inc.'s ROE?
How is the ROE calculated for Arcturus Therapeutics Holdings Inc. (ARCT)?
What is the highest ROE for Arcturus Therapeutics Holdings Inc. (ARCT)?
What is the 3-year average ROE for Arcturus Therapeutics Holdings Inc. (ARCT)?
What is the 5-year average ROE for Arcturus Therapeutics Holdings Inc. (ARCT)?
How does the current ROE for Arcturus Therapeutics Holdings Inc. (ARCT) compare to its historical average?